CVac: Interim Phase II data

Interim data from the open-label, international Phase II CAN-003 trial 63 ovarian cancer patients in remission after first- or second-line therapy showed that CVac led to a median PFS of 365 days as of Aug. 17, 2012, vs. 321 days for observational standard of care. Median PFS for the first 7 patients enrolled in the trial that were not randomized and received CVac was 421 days. Median PFS for patients in remission after first-line therapy was 326 days and has not yet been reached in patients in remission after second-line therapy. Additionally, preliminary intracellular cytokine staining data in 3 patients treated with CVac showed that the product produced a mucin 1 ( MUC1; CD227)-specific cytotoxic T cell response, while no response was observed in healthy volunteers or untreated patients. CVac was well tolerated. Patients received CVac every 4 weeks for 24 weeks followed by booster injections every 8 weeks until week 48. Data were presented at the International Gynecologic Cancer Society meeting in Vancouver. ...